Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)

Go back to Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
Otter Lake Resources, Inc. New (NASDAQ: OTLK) Delayed: 0.56 --0 (-0%)
Previous Close $0.56    52 Week High $0.03 
Open $0.56    52 Week Low $0.01 
Day High $0.56    P/E N/A 
Day Low $0.56    EPS $0.00 
Volume 46,344